Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Robert Jabulowsky has more than 9 years of experience in academic translational cancer research and industrial pharmaceutical development. Dr. Jabulowsky joined BioNTech AG (Mainz, Germany) in 2012 and as Deputy Head of Project Management he is responsible for the management and translation of innovative therapeutic concepts into clinical testing. Founded in 2008, BioNTech AG is an immunotherapy leader with bench-to-market capabilities, developing truly personalized, well-tolerated and potent treatments for cancer and other diseases. Established by clinicians and scientists BioNTech is pioneering disruptive technologies ranging from individualized mRNA based medicines through innovative Chimeric Antigen Receptors /T-cell Receptor-based products and novel antibody checkpoint immunomodulators.
Robert Jabulowsky holds a diploma in Biology and a PhD in Pharmacy from the University of Frankfurt, Germany.